| Literature DB >> 24155665 |
Marcel Adler1, Eduard Murani, Siriluck Ponsuksili, Klaus Wimmers.
Abstract
BACKGROUND: The identification of key genes and regulatory networks in the transcriptomic responses of blood cells to antigen stimulation could facilitate the understanding of host defence and disease resistance. Moreover, genetic relationships between immunocompetence and the expression of other phenotypes, such as those of metabolic interest, are debated but incompletely understood in farm animals. Both positive and negative associations between immune responsiveness and performance traits such as weight gain or lean growth have been reported. We designed an in vivo microarray study of transcriptional changes in porcine peripheral blood mononuclear cells (PBMCs) during the immune response to tetanus toxoid (TT) as a model antigen for combined cellular (Th1) and humoral (Th2) responses. The aim of the study was to investigate the responsiveness of PBMCs against the background of divergent lean growth (LG) performance and anti-TT antibody (AB) titers and to compare lean growth and humoral immune performance phenotypes.Entities:
Keywords: leukocyte; microarray; pathway analysis; porcine; tetanus vaccination
Mesh:
Substances:
Year: 2013 PMID: 24155665 PMCID: PMC3805897 DOI: 10.7150/ijbs.6769
Source DB: PubMed Journal: Int J Biol Sci ISSN: 1449-2288 Impact factor: 6.580
Figure 1Experimental design. Five-week-old piglets were vaccinated twice with TT. Directly before the first (day 0) and the second (day 14) vaccination as well at day 28 blood samples were collected and PBMCs were isolated. Anti-TT antibody titers were quantified by ELISA from day 28 plasma samples. Animals were then performance-tested. Performance data and AB titers were interpreted as a basis for the identification of divergent phenotypes of lean growth performance and humoral immune response, respectively. Finally, expression profiles of divergent phenotypes for lean growth and humoral immune performance were compared.
Key traits used for phenotype rating of high lean growth and low lean growth performance.
| Trait | High lean growth | Low lean growth | High | ||||
|---|---|---|---|---|---|---|---|
| Mean | SD | Mean | SD | p-value | |||
| Average backfat (cm) | 1.86 | 0.21 | 2.44 | 0.35 | 5.93 x E-07 | ||
| Fat area (cm2) | 14.9 | 2.8 | 21.5 | 3.8 | 3.66E-07 | ||
| Loin eye area (cm2) | 53.0 | 4.4 | 48.0 | 6.2 | 6.34E-03 | ||
| Meat to fat ratio | 3.7 | 0.9 | 2.3 | 0.6 | 1.55E-06 | ||
| Lean mean content (%) | 59.9 | 1.9 | 54.6 | 3.7 | 4.75E-06 | ||
Numbers of differentially-expressed (DE-) genes from comparison of lean growth performance and antibody titers
| Main phenotype comparisons | ||
|---|---|---|
| Lean growth performance: | Antibody titer: | |
| Number of DE-genes | 574 | 522 |
| Transcript Abundance > | 366 | 133 |
| Transcript Abundance < | 208 | 389 |
Top 10 canonical pathways for lean growth performance (a) and antibody titer (b) phenotype comparisons
| Canonical Pathway | Pathway category | -log p-value | Genes | Transcript abundance | |
|---|---|---|---|---|---|
| > | < | ||||
| T Cell Receptor Signaling | 1 | 3.84 | 13 | 12 | 1 |
| PKCθ Signaling in T Lymphocytes | 1 | 3.84 | 14 | 11 | 3 |
| CD28 Signaling in T Helper Cells | 1 | 3.84 | 14 | 10 | 4 |
| CTLA4 Signaling in Cytotoxic T Lymphocytes | 1 | 3.75 | 12 | 10 | 2 |
| Role of NFAT in Regulation of the IR | 1,2,3 | 3.42 | 16 | 11 | 5 |
| Phospholipase C Signaling | 3 | 3.42 | 19 | 13 | 6 |
| iCOS-iCOSL Signaling in T Helper Cells | 1 | 3.16 | 12 | 8 | 4 |
| Protein Kinase A Signaling | 3 | 3.16 | 25 | 14 | 11 |
| Calcium-induced T Lymphocyte Apoptosis | 4,1 | 2.99 | 9 | 7 | 2 |
| CCR5 Signaling in Macrophages | 1,5 | 2.63 | 9 | 7 | 2 |
| Integrin Signaling | 3,6,7 | 8.08 | 24 | 1 | 23 |
| Phospholipase C Signaling | 3 | 4.86 | 21 | 4 | 17 |
| Clathrin-mediated Endocytosis Signaling | 1,8,9 | 4.70 | 18 | 1 | 17 |
| IL-8 Signaling | 1,5 | 4.70 | 18 | 3 | 15 |
| Thrombin Signaling | 10 | 4.56 | 18 | 2 | 16 |
| Role of NFAT in Regulation of the IR | 1,2,3 | 4.56 | 17 | 3 | 14 |
| PTEN Signaling | 4 | 4.56 | 14 | 0 | 14 |
| P2Y Purigenic Receptor Signaling Pathway | 10 | 4.26 | 14 | 2 | 12 |
| Ephrin Receptor Signaling | 9 | 4.01 | 16 | 2 | 14 |
| CXCR4 Signaling | 1,5 | 3.94 | 15 | 1 | 14 |
Pathway categories:
1 Cellular immune response; 2 Humoral immune response;
3 Intracellular and second messenger signalling; 4 Apoptosis;
5 Cytokine signalling; 6 Cellular growth, proliferation and development;
7 Cell cycle regulation; 8 Pathogen-influenced signaling;
9 Organismal growth and development; 10 Cardiovascular signaling;
Abbreviation: IR Immune response
Top 15 biofunctions for lean growth performance (a) and antibody titer (b) phenotype comparisons
| Activation | # Genes | Predicted | ||
|---|---|---|---|---|
| Annotated functions | z-score | -log p-value | involved | activation state |
| organismal death | -4.39 | 2.90 | 77 | < |
| development of leukocytes | 3.51 | 4.29 | 39 | > |
| differentiation of lymphocytes | 3.38 | 6.46 | 40 | > |
| cellular homeostasis | 3.35 | 5.15 | 74 | > |
| lymphocyte homeostasis | 3.31 | 4.14 | 36 | > |
| T cell development | 3.28 | 4.04 | 34 | > |
| development of blood cells | 3.25 | 3.94 | 41 | > |
| development of lymphocytes | 3.23 | 4.18 | 37 | > |
| T cell homeostasis | 3.18 | 4.19 | 35 | > |
| development of cardiovascular system | 3.04 | 3.79 | 56 | > |
| differentiation of mononuclear leucocytes | 2.97 | 6.46 | 42 | > |
| development of blood vessel | 2.94 | 2.59 | 42 | > |
| differentiation of B lymphocytes | 2.78 | 3.48 | 19 | > |
| differentiation of leucocytes | 2.70 | 6.25 | 47 | > |
| quantity of helper T lymphocytes | 2.59 | 2.54 | 15 | > |
| adhesion of blood cells | -4.01 | 1.75 | 22 | < |
| aggregation of cells | -3.92 | 3.68 | 24 | < |
| aggregation of blood cells | -3.58 | 3.97 | 21 | < |
| aggregation of blood platelets | -3.32 | 4.60 | 142 | < |
| proliferation of cells | -2.99 | 5.52 | 83 | < |
| differentiation of cells | -2.96 | 3.03 | 25 | < |
| cell transformation | -2.79 | 1.89 | 34 | < |
| differentiation of blood cells | -2.78 | 1.49 | 43 | < |
| activation of cells | -2.61 | 1.64 | 98 | < |
| cell movement | -2.48 | 7.32 | 23 | < |
| hemostasis | -2.47 | 5.77 | 39 | < |
| activation of blood cells | -2.38 | 2.37 | 89 | < |
| migration of cells | -2.37 | 6.50 | 34 | < |
| proliferation of T lymphocytes | -2.36 | 2.52 | 55 | < |
| cellular homeostasis | -2.31 | 1.56 | 35 | < |
Numbers of DE-genes from differentiated comparisons between lean growth performance and antibody titers
| Differentiated comparisons for high (hi) and low (lo) lean growth (LG) and antibody (AB) phenotypes | ||||
|---|---|---|---|---|
| hiLG+hiAB | hiLG+hiAB | loLG+hiAB | hiLG+loAB | |
| Number of DE-genes | 432 | 407 | 489 | 441 |
| Transcript Abundance > | 311 | 111 | 129 | 293 |
| Transcript Abundance < | 121 | 296 | 360 | 148 |
Figure 2Affected canonical pathways revealed by differentiated comparisons of four phenotypic groups. Symbols > and < refer to overall transcript abundance and were set if more than 75 % of involved DE-genes showed positive or negative fold change, respectively.
Figure 3Altered biofunctions revealed by differentiated comparison between four phenotypic groups. Symbols > and < refer to IPA prediction of increased (>) or decreased (<) activation state of the respective biofunction.